Scientists hunt for genetic clues in rare blood disorders
NCT ID NCT05028621
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The goal is to better understand these disorders and open doors to personalized treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify genetic targets for new treatments in rare blood diseases.
- What could go wrong
- The study is exploratory and currently suspended, so results may be delayed or not lead to direct treatments. It is small and early-stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN'S DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive study tracks hidden toll of rare immune diseases
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- Rare disease study probes hidden brain effects
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- New targeted drug combo aims to curb relapse in kids with rare immune disorder
- New pill could spare kids with rare bone disease from chemo